FibroGen Inc

Most Recent

  • uploads///pills _
    Earnings Report

    What Wall Street Recommends for Amarin after Q4 2018 Results

    On February 27, Amarin (AMRN) closed at $21.18, 5.85% higher than its previous closing price, 801.28% higher than its 52-week low of $2.35, and 9.24% below its 52-week high of $23.33.

    By Margaret Patrick
  • uploads///FGEN
    Company & Industry Overviews

    Understanding FibroGen’s Research Pipeline

    Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200.

    By Kenneth Smith
  • uploads///Esbriet revenues
    Company & Industry Overviews

    Esbriet Could Boost Roche’s Revenue Growth in 2H17

    In the first half of 2017, Roche’s (RHHBY) Esbriet reported revenues of CHF 418.0 million, which reflected a ~16.0% growth on a YoY basis.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.